MedTrace Logo

Human Placental-Derived Stem Cell Transplantation

NCT01586455 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2022-10-25

No results posted yet for this study

Summary

The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.

Conditions

  • Mucopolysaccharidosis I
  • Mucopolysaccharidosis VI
  • Adrenoleukodystrophy
  • Niemann-Pick Disease
  • Metachromatic Leukodystrophy
  • Wolman Disease
  • Krabbe's Disease
  • Gaucher's Disease
  • Fucosidosis
  • Batten Disease
  • Severe Aplastic Anemia
  • Diamond-Blackfan Anemia
  • Amegakaryocytic Thrombocytopenia
  • Myelodysplastic Syndrome
  • Acute Myelogenous Leukemia
  • Acute Lymphocytic Leukemia

Interventions

DRUG

Human Placental Derived Stem Cell

Infusions of thawed HPDSC to be given following UCB infusion.

Sponsors & Collaborators

  • New York Medical College

    lead OTHER

Principal Investigators

  • Mitchell S Cairo, MD · New York Medical College

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
0 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2020-06-30
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586455 on ClinicalTrials.gov